The Danish Medicines Company has printed the most recent outcomes of the nation's ongoing medical hashish pilot program.

Denmark launched its medicinal hashish pilot program in 2018, which permits medical doctors to prescribe cannabis-based merchandise for sufferers with sure qualifying situations.

Now officers have printed the most recent outcomes of this system, which is predicted to final till 2025.

U report outlines key data relating to suspected adversarial reactions, consumption tendencies and basic security of prescribed hashish merchandise through the interval 2021-2022.

Overview of unwanted side effects

Throughout the specified interval, the company obtained 19 studies of suspected adversarial reactions associated to hashish merchandise lined by the pilot program. This can be a important discount from the 20 studies obtained in 2020.

The studies have been divided into 9 instances in 2021 and 10 in 2022, solely one in all which was categorized as a suspected critical adversarial response.

Regardless of a rise within the variety of prescriptions for hashish merchandise in 2021 and 2022, the annual studies of adversarial reactions decreased by half. The Danish Medicines Company confirms that these studies didn’t reveal any security issues and that they didn’t establish any unwanted side effects within the batch through the interval.

The doc gives an in depth evaluation of the data unwanted side effects, classifying them into two classes: critical and non-serious. A lot of the studies (18 of 19) have been for suspected non-serious unwanted side effects, similar to dizziness, upset abdomen, anxiousness and diarrhea. One report famous a suspected critical aspect impact, particularly a substance-induced psychotic dysfunction attributed to an overdose.

The company fastidiously analyzed every report back to assess the potential cause-effect relationship between the ultimate hashish product and the reported aspect impact. It needs to be famous that each one the reported unwanted side effects have been already identified for the licensed medicines containing hashish and no new dangers have been recognized.